---
title: "SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) | SRXH Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294794808.md"
description: "SRX Global Inc. announced the acquisition of a stake in Vistagen Therapeutics, a late clinical-stage biopharmaceutical company focused on neuroscience and intranasal product candidates. SRX views Vistagen shares as undervalued and intends to engage with its leadership to unlock shareholder value."
datetime: "2026-08-04T01:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294794808.md)
  - [en](https://longbridge.com/en/news/294794808.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294794808.md)
generator: "portal-rs"
---

# SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) | SRXH Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has acquired a stake in Vistagen Therapeutics, Inc. (Vistagen) (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines.

The Company views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team and Board of Directors to discuss ideas on how to unlock shareholder value.

**About SRX Global Inc.**

SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "intend," "aim," "plan," "may," "could," "target," and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals, market conditions, regulatory considerations, and other risks described in the Company's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.

**Company Contact**

SRX Global  
Kent Cunningham, Chief Executive Officer

**Investor Relations Contact**

KCSA Strategic Communications  
Valter Pinto, Managing Director  
212-896-1254  
srx@kcsa.com

### Related Stocks

- [VTGN.US](https://longbridge.com/en/quote/VTGN.US.md)
- [SRXH.US](https://longbridge.com/en/quote/SRXH.US.md)

## Related News & Research

- [Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth](https://longbridge.com/en/news/290007525.md)
- [SRX Global sells 3,579 Series C preferred shares in private placement valued at $2.86 million](https://longbridge.com/en/news/297369039.md)
- [Infrastructure Capital Advisors LLC Has $4.22 Million Stock Holdings in GE Vernova Inc. $GEV](https://longbridge.com/en/news/297297006.md)
- [Maxi Investments CY Ltd Makes New $2 Million Investment in GE Vernova Inc. $GEV](https://longbridge.com/en/news/297297000.md)
- [VTGN: Improved financials and promising clinical signals for fasedienol, with cash runway into 2027](https://longbridge.com/en/news/295937392.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**